Abstract B048: Activation of PKC inhibits oncogenic KRAS-driven malignancies
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-b048
Abstract: The extremely high mutation rate of KRAS in three of the top four deadly cancers (lung, colon, and pancreas) makes it a major target in anticancer drug discovery. However, no effective anti-KRAS inhibitors have yet… read more here.
Keywords: driven malignancies; prostratin; activation pkc; pkc ... See more keywords